title: Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: a tale of two systems.
abstract: Gait and balance disorders unresponsive to dopaminergic drugs in Parkinson's disease (PD) are secondary to lesions located outside the dopaminergic system. However, available animal models of PD fail to display l-3,4-dihydroxyphenylalanine (DOPA)-responsive parkinsonism and drug-resistant gait and balance disorders, and this lack of appropriate model could account for the deficit of efficient treatments. Because the pedunculopontine nucleus (PPN) plays an important role in locomotion control, we conducted the present study to investigate the consequences of combined dopaminergic and PPN lesions in a same animal. We used macaques that received first 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication to render them parkinsonian and then local stereotaxic lesion of the PPN. Adding bilateral PPN lesions in MPTP-lesioned macaques induced dopamine-resistant gait and balance disorders but unexpectedly improved hypokinesia. Additional MPTP injections resulted in the association of a severe DOPA-responsive parkinsonism together with DOPA-unresponsive gait disorders. Histological examination assessed a severe dopaminergic degeneration and a significant loss of PPN cholinergic neurons. We observed similar results in aged monkeys intoxicated with MPTP: they developed severe DOPA-responsive hypokinesia and tremor together with unresponsive gait and balance disorders and displayed dopaminergic lesion and a weak but significant cholinergic PPN lesion. Our results highlight the complex role of the cholinergic PPN neurons in the pathophysiology of PD because its lesion induces a dual effect with an improvement of hypokinesia contrasting with a worsening of DOPA-unresponsive gait and balance disorders. Thus, we obtained a primate model of PD that could be useful to test symptomatic treatments for these heavily disabling symptoms.
authors.affiliation: CR-ICM, UMR-S975, Université Pierre et Marie Curie-Paris 6, Paris, France, INSERM, U975, Paris, France. david.grabli@psl.aphp.fr
authors.forename: David
authors.initials: D
authors.lastname: Grabli
authors.forename: Carine
authors.initials: C
authors.lastname: Karachi
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Folgoas
authors.forename: Morgane
authors.initials: M
authors.lastname: Monfort
authors.forename: Dominique
authors.initials: D
authors.lastname: Tande
authors.forename: Stewart
authors.initials: S
authors.lastname: Clark
authors.forename: Olivier
authors.initials: O
authors.lastname: Civelli
authors.forename: Etienne C
authors.initials: EC
authors.lastname: Hirsch
authors.forename: Chantal
authors.initials: C
authors.lastname: François
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D002452:Cell Count; D059329:Cholinergic Neurons / Q000187:drug effects / Q000473:pathology* / Q000502:physiology; D059290:Dopaminergic Neurons / Q000187:drug effects / Q000473:pathology* / Q000502:physiology; D005260:Female; D007794:Lameness, Animal / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology*; D008252:Macaca fascicularis; D008297:Male; D020734:Parkinsonian Disorders / Q000473:pathology / Q000503:physiopathology*; D045042:Pedunculopontine Tegmental Nucleus / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D013378:Substantia Nigra / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology
chemical_list: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine